6:06 PM
 | 
Dec 20, 2012
 |  BC Extra  |  Clinical News

MDCO reports first Phase III data for ABSSI compound

The Medicines Co. (NASDAQ:MDCO) said a single dose of IV oritavancin met the FDA-defined and EMA-defined primary endpoints of non-inferiority to twice-daily vancomycin for 7-10 days in the 968-patient Phase III SOLO-1 trial to treat acute bacterial skin...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >